Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Photo of masked woman receiving post-vaccination plaster.

MRC Weatherall Institute of Molecular Medicine researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

While this is expected to improve with the second dose, this important finding may help influence the design of future vaccination strategies, with further work needed to determine the optimal interval between vaccine doses in certain groups.

The team from the University of Oxford’s MRC-Weatherall Institute of Molecular Medicine (MRC-WIMM) Molecular Haematology Unit studied 60 patients with chronic myeloid blood cancers under the care of the Myeloid Team at the Churchill Hospital, Oxford University Hospitals NHS Foundation Trust.

The study, published in the British Journal of Haematology, was supported by the NIHR Oxford Biomedical Research Centre.

These patients had a variety of blood cancers, including: chronic myeloid leukaemia (CML), essential thrombocythemia (ET) polycythaemia (PV), myelofibrosis (MF) and myelodysplastic syndromes (MDS). As these cancers do not involve the antibody-producing B cells in the blood, antibody responses might be expected to be reasonably normal.

Their antibody levels were measured after they had received their first dose of the COVID-19 vaccine. Most patients developed antibodies in response to the vaccination, and the Pfizer and Oxford/AstraZeneca vaccines were found to be equally effective.

“We found that the proportion of patients with a detectable antibody response two weeks after the first vaccine dose was significantly lower in the patient group than in healthy controls of similar age to the patients,” explained Dr Onima Chowdhury, Consultant Haematologist and one of the lead authors of the study. 

“Around 60 per cent of patients had a positive antibody test after the first dose, compared to 95% of the healthy controls. This difference was particularly marked in patients with myeloproliferative neoplasms who were receiving certain treatments, while other subgroups such as patients treated with interferon or those with chronic myeloid leukaemia responded almost as well as the controls.”

Fellow author Dr Beth Psaila, Cancer Research UK Advanced Clinician Scientist at the MRC-WIMM and Oxford BRC Senior Fellow, said: “The COVID-19 pandemic has had a severe impact on patients with blood cancers, and the roll-out of the vaccines has been hugely important to enable vulnerable individuals to emerge from shielding.

“However, given that patients with cancer were not included in the initial trials of the COVID-19 vaccines, it is important that we carefully analyse responses to ensure that patients who are vulnerable to severe infection are optimally protected.

Dr Psaila added: “This study showed that in certain patient groups, responses to the first vaccine dose were disappointing. However, we are continuing to study responses to the second ‘booster’ dose and are now working collaboratively with other UK centres as part of a taskforce coordinated by Blood Cancer UK to shed more light on these findings in larger cohorts of patients, and to carefully study the impact of certain treatments on immunity in patients with myeloid blood cancers.”

Dr Chowdhury concluded: “Although responses to the booster doses are encouraging, and severe COVID-19 infections appear to be rare in patients following vaccination, our finding that responses to the first dose may be impaired in this particular patient group was unexpected and may help guide optimal design of vaccination schedules in efforts to ensure that all vulnerable patients are adequately protected from severe COVID-19 infection.”

Similar stories

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.